PACB News and Press, Pacific Biosciences of California Inc. From 12/06/22

PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing PR Newswire Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNews...

Although PacBio ( NASDAQ: PACB ) just beat on the bottom line in its Q3 2022 results, the biotech saw its net loss widen 8% to ~$77M compared to the year-ago period. Revenue of ~$32M, a ~7% year-over-year decline, was a miss. Total operating expenses of ~$88.3M in ...

Pacific Biosciences of California, Inc. (PACB) Q3 2022 Earnings Conference Call November 07, 2022 05:00 PM ET Company Participants Todd Friedman - Director of Investor Relations Christian Henry - President & Chief Executive Officer Susan Kim - Chief Financial...

Pacific Biosciences of California press release ( NASDAQ: PACB ): Q3 Non-GAAP EPS of -$0.32 beats by $0.01 . Revenue of $32.31M (-7.4% Y/Y) misses by $3.09M . Instrument revenue of $11.4 million, compared with $15.9 million in the prior year period. Consuma...

PacBio Announces Third Quarter 2022 Financial Results PR Newswire MENLO PARK, Calif. , Nov. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022 . Third quarter resu...

PacBio Announces that Euan Ashley, M.D., Ph.D., Joseph Puglisi, Ph.D., and Jay Shendure, Ph.D., Join Newly Created Scientific Advisory Board PR Newswire World Class Team Will Provide Strategic Guidance and Direction for PacBio's Research and Development Activities ...

Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...

Summary PACB's management believes that it is the only sequencing technology company offering HiFi reads with a 99.9% accuracy. Sequel II systems realized higher selling prices including a multi-instrument order with greater consumable service revenue volume in Q2 2022. PACB i...

Pacific Biosciences of California ( NASDAQ: PACB ) is launching a new more affordable gene-sequencing system called Revio which will enable customers to scale the use of the company's HiFi sequencing technology. The company said on Tuesday that the long-read seque...

PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000 PR Newswire Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revi...